The Australian Fragile-X Syndrome Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Fragile X Syndrome is characterized by moderate intellectual disability in affected males and mild intellectual disability in affected females. Distinctive physical features are sometimes present in affected males including a large head, long face, prominent forehead and chin, protruding ears, loose joints and large testes, but these features develop over time and may not be obvious until puberty. Motor and language delays are usually present but also become more apparent over time. Behavioural abnormalities including autistic behaviours are common. Men are more often affected by this disorder than women. About 15% men and 5% women suffering from Fragile X Syndrome can experience seizures.
However, the presence of a strong pipeline that increases the focus of pharmaceuticals & biotechnology companies on conducting research programs for the effective treatment of syndrome also boosts up the market growth. Moreover, rising cases of genetic mutation syndromes and increases in unhealthy lifestyles (such as smoking cigarettes, alcohol drinking, and others) by women during pregnancy also boost up the market growth. But, lack of awareness of the syndrome and the high cost of treatment in developing countries may hamper the Fragile X Syndrome (FXS) Therapeutics market.